FDA Approves Gemtesa for Overactive Bladder in Men With BPH
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 2, 2025 -- Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic hyperplasia (BPH), according to a press release published by Sumitomo Pharma.
Gemtesa, a β3 adrenergic receptor agonist, dosed once daily (75 mg), has been approved for men with OAB symptoms, including urinary incontinence, urgency, and urinary frequency, who are receiving pharmacologic treatment for BPH.
The approval was based on results from a 24-week phase 3 study of Gemtesa versus placebo in about 1,100 men with OAB symptoms receiving pharmacologic therapy for BPH. All coprimary end points at week 12 were met, with significant reductions from baseline seen in the average number of micturition episodes per day and in the average number of daily urgency episodes with Gemtesa versus placebo. In addition, at 12 weeks, there was a reduction in instances of urge urinary incontinence episodes per day. Adverse reactions of hypertension and urinary tract infection exceeding the placebo rate occurred in ≥2 percent of patients treated with Gemtesa.
"The FDA's expanded approval of Gemtesa is an important milestone for the men with unresolved symptoms of OAB while being treated for BPH, which underscores our urgency to deliver for those affected by conditions with unmet need," Tsutomu Nakagawa, Ph.D., president and chief executive officer of Sumitomo Pharma America Inc., said in a statement.
Approval of Gemtesa was granted to Sumitomo Pharma.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Blue Laser Vaporization Effective for Benign Prostatic Hyperplasia
TUESDAY, April 8, 2025 -- Blue laser vaporization alleviates lower urinary tract symptoms while preserving sexual function in patients undergoing benign prostatic hyperplasia...
Geriatric Nutritional Risk Index Predictive for Overactive Bladder
MONDAY, April 7, 2025 -- The Geriatric Nutritional Risk Index (GNRI) is a reliable predictive marker for overactive bladder (OAB) in the elderly, according to a study published...
Invasive Bladder Pressure Tests for Refractory Overactive Bladder May Be Avoided
TUESDAY, April 1, 2025 -- Urodynamics plus comprehensive clinical assessment (CCA) is not superior to CCA only for women with refractory overactive bladder or urgency predominant...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.